Mykhailo B. Todurov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mykhailo B. Todurov has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Borys M. Todurov
Shupyk National Healthcare University of Ukraine, Kyiv
9 shared publications - Stepan Maruniak
Department of Anesthesiology and Extracorporeal Treatment, Heart Institute of the Ministry of Health of Ukraine
8 shared publications - Serhii M. Sudakevych
State Institution "Heart Institute of the Ministry of Health of Ukraine" Kyiv, Ukraine; Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
6 shared publications - Oleg V. Zelenchuk
Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine; Heart Institute of the Ministry of Health of Ukraine, Kyiv, Ukraine
4 shared publications - Sofia M. Chaikovska
Heart Institute of the Ministry of Health of Ukraine, Kyiv
4 shared publications - Svitlana Romanenko
Heart Institute of the Ministry of Health of Ukraine, Kyiv, Ukraine
3 shared publications
Latest Publications
- 23 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Planned Versus Standby V‐A ECMO Strategy During High‐Risk PCI: A Retrospective Cohort Study
Background: The role of mechanical circulatory support (MCS) in high‐risk percutaneous coronary intervention (HR‐PCI) remains controversial, and the optimal timing of its initiation is not well defined. Veno‐arterial extracorporeal membrane oxygenation (V‐A ECMO) provides full hemodynamic support; however, comparative data on planned versus standby strategies are limited. Aim: To compare clinical outcomes of planned versus standby V‐A ECMO support in patients undergoing elective HR‐PCI, with a focus on the impact of timing of ECMO initiation. Methods: This single‐center retrospective observational study included 74 consecutive patients who underwent high‐risk PCI between 2019 and 2025 and were managed according to a preprocedurally determined V‐A ECMO strategy. Before PCI, the multidisciplinary Heart Team selected either a planned strategy ( n = 43), in which V‐A ECMO was initiated before PCI, or a standby strategy ( n = 31), in which ECMO equipment and vascular access were prepared in advance, but ECMO was initiated only in response to predefined intraprocedural hemodynamic deterioration. The primary endpoint was in‐hospital major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death, myocardial infarction, stroke, and repeat revascularization. Results: No statistically significant differences were observed in the measured baseline variables. ECMO support during PCI was required in 19/32 (61.3%) of patients in the standby‐strategy group. The incidence of in‐hospital MACCE was significantly higher in the standby‐strategy group compared with the planned‐strategy group (48.4% vs. 14.0%, p = 0.002). The standby‐strategy group also had longer ICU stay (8 [5–12] vs. 6 [4–9] days, p = 0.03) and hospital stay (15 [11–20] vs. 12 [9–16] days, p = 0.02), as well as higher vasoactive‐inotropic scores ( p = 0.033). In multivariable analysis, the standby strategy was associated with higher odds of in‐hospital MACCE after adjustment (adjusted OR, 4.20; 95% CI, 1.35–13.10; p = 0.013). Conclusions: In this single‐center retrospective cohort of patients undergoing elective HR‐PCI, a planned V‐A ECMO strategy was associated with a lower incidence of in‐hospital MACCE than a standby strategy. Given the nonrandomized treatment allocation, inclusion of standby patients who did not ultimately require ECMO, and limited number of events, these findings are hypothesis‐generating and do not establish a causal benefit of planned ECMO or harm from rescue initiation.
- 23 September 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Planned Versus Standby V‐A ECMO Strategy During High‐Risk PCI: A Retrospective Cohort Study
Background: The role of mechanical circulatory support (MCS) in high‐risk percutaneous coronary intervention (HR‐PCI) remains controversial, and the optimal timing of its initiation is not well defined. Veno‐arterial extracorporeal membrane oxygenation (V‐A ECMO) provides full hemodynamic support; however, comparative data on planned versus standby strategies are limited. Aim: To compare clinical outcomes of planned versus standby V‐A ECMO support in patients undergoing elective HR‐PCI, with a focus on the impact of timing of ECMO initiation. Methods: This single‐center retrospective observational study included 74 consecutive patients who underwent high‐risk PCI between 2019 and 2025 and were managed according to a preprocedurally determined V‐A ECMO strategy. Before PCI, the multidisciplinary Heart Team selected either a planned strategy ( n = 43), in which V‐A ECMO was initiated before PCI, or a standby strategy ( n = 31), in which ECMO equipment and vascular access were prepared in advance, but ECMO was initiated only in response to predefined intraprocedural hemodynamic deterioration. The primary endpoint was in‐hospital major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death, myocardial infarction, stroke, and repeat revascularization. Results: No statistically significant differences were observed in the measured baseline variables. ECMO support during PCI was required in 19/32 (61.3%) of patients in the standby‐strategy group. The incidence of in‐hospital MACCE was significantly higher in the standby‐strategy group compared with the planned‐strategy group (48.4% vs. 14.0%, p = 0.002). The standby‐strategy group also had longer ICU stay (8 [5–12] vs. 6 [4–9] days, p = 0.03) and hospital stay (15 [11–20] vs. 12 [9–16] days, p = 0.02), as well as higher vasoactive‐inotropic scores ( p = 0.033). In multivariable analysis, the standby strategy was associated with higher odds of in‐hospital MACCE after adjustment (adjusted OR, 4.20; 95% CI, 1.35–13.10; p = 0.013). Conclusions: In this single‐center retrospective cohort of patients undergoing elective HR‐PCI, a planned V‐A ECMO strategy was associated with a lower incidence of in‐hospital MACCE than a standby strategy. Given the nonrandomized treatment allocation, inclusion of standby patients who did not ultimately require ECMO, and limited number of events, these findings are hypothesis‐generating and do not establish a causal benefit of planned ECMO or harm from rescue initiation.
- Open Access
- 12 August 2026
- Published by Danylo Halytskyi Lviv National Medical University in Proceeding of the Shevchenko Scientific Society. Medical Sciences
- Vol. 2 (78)
Prophylactic Use of V-A ECMO During High-Risk Percutaneous Coronary Interventions: A Single-Center Study
Background. High-risk percutaneous coronary interventions (high-risk PCI) in patients with complex coronary artery disease and reduced left ventricular systolic function are associated with a substantial risk of hemodynamic instability and periprocedural complications. Mechanical circulatory support may improve the safety of these procedures by maintaining adequate systemic perfusion during technically demanding stages of the intervention. Objective: To evaluate the safety and results of prophylactic veno-arterial extracorporeal membrane oxygenation (V-A ECMO) during high-risk PCI in patients with coronary artery disease and to identify factors associated with in-hospital mortality. Methods. A single-center retrospective observational study was conducted, including consecutive patients who underwent elective high-risk PCI with prophylactic V-A ECMO support between 2019 and 2025. The primary endpoint was in-hospital mortality. We used logistic regression to identify predictors of mortality. Results. A total of 43 patients were included in the analysis (mean age 66.1 ± 8.9 years; 74.4% male). The mean left ventricular ejection fraction was 31.9 ± 6.8%, and the mean SYNTAX score was 32.4 ± 6.8. Successful revascularization was achieved in 90.7% of cases, and ECMO weaning at the end of the procedure was possible in 88.4% of patients. In-hospital mortality was 14.0%. Major bleeding occurred in 20.9% of patients, vascular complications in 11.6%, and acute kidney injury in 23.3%. In multivariable analysis, the maximum vasoactive-inotropic score (VIS) was identified as an independent predictor of in-hospital mortality (OR 1.10; 95% CI 1.01–1.21; p = 0.041). Conclusions. Prophylactic V-A ECMO enabled elective high-risk PCI in a highly selected cohort with complex coronary anatomy and impaired left ventricular function. However, the substantial in-hospital mortality and complication rates, together with the retrospective design and absence of a control group, preclude conclusions regarding clinical effectiveness. Prospective controlled studies are required to determine whether prophylactic V-A ECMO improves outcomes compared with unsupported PCI or other mechanical circulatory support strategies.
- 12 August 2026
- Published by Danylo Halytskyi Lviv National Medical University in Proceeding of the Shevchenko Scientific Society. Medical Sciences
- Vol. 2 (78)
Open AccessProphylactic Use of V-A ECMO During High-Risk Percutaneous Coronary Interventions: A Single-Center Study
Background. High-risk percutaneous coronary interventions (high-risk PCI) in patients with complex coronary artery disease and reduced left ventricular systolic function are associated with a substantial risk of hemodynamic instability and periprocedural complications. Mechanical circulatory support may improve the safety of these procedures by maintaining adequate systemic perfusion during technically demanding stages of the intervention. Objective: To evaluate the safety and results of prophylactic veno-arterial extracorporeal membrane oxygenation (V-A ECMO) during high-risk PCI in patients with coronary artery disease and to identify factors associated with in-hospital mortality. Methods. A single-center retrospective observational study was conducted, including consecutive patients who underwent elective high-risk PCI with prophylactic V-A ECMO support between 2019 and 2025. The primary endpoint was in-hospital mortality. We used logistic regression to identify predictors of mortality. Results. A total of 43 patients were included in the analysis (mean age 66.1 ± 8.9 years; 74.4% male). The mean left ventricular ejection fraction was 31.9 ± 6.8%, and the mean SYNTAX score was 32.4 ± 6.8. Successful revascularization was achieved in 90.7% of cases, and ECMO weaning at the end of the procedure was possible in 88.4% of patients. In-hospital mortality was 14.0%. Major bleeding occurred in 20.9% of patients, vascular complications in 11.6%, and acute kidney injury in 23.3%. In multivariable analysis, the maximum vasoactive-inotropic score (VIS) was identified as an independent predictor of in-hospital mortality (OR 1.10; 95% CI 1.01–1.21; p = 0.041). Conclusions. Prophylactic V-A ECMO enabled elective high-risk PCI in a highly selected cohort with complex coronary anatomy and impaired left ventricular function. However, the substantial in-hospital mortality and complication rates, together with the retrospective design and absence of a control group, preclude conclusions regarding clinical effectiveness. Prospective controlled studies are required to determine whether prophylactic V-A ECMO improves outcomes compared with unsupported PCI or other mechanical circulatory support strategies.
- Open Access
- 16 July 2026
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 4,p. 51-61
IMPACT OF THE TIMING OF RENAL REPLACEMENT THERAPY INITIATION ON TREATMENT OUTCOMES IN PATIENTS WITH CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY: A RETROSPECTIVE STUDY
Introduction. Acute kidney injury (AKI) following cardiac surgery remains one of the leading predictors of adverse clinical outcomes. Despite modern perfusion and intensive care technologies, the optimal timing of renal replacement therapy (RRT) initiation in AKI remains controversial.Aim. To assess the impact of RRT initiation timing on in-hospital mortality and renal function recovery in patients with AKI after cardiac surgery with cardiopulmonary bypass.Materials and methods. A retrospective single-center analysis was conducted in patients who underwent cardiac surgery with cardiopulmonary bypass between 2022 and 2025. Among 5,289 operated patients, AKI according to KDIGO criteria developed in 1,358 (25.7%), and 58 (4.27%) required RRT. Depending on treatment timing, patients were divided into early RRT initiation (n = 27; immediately after stage III AKI diagnosis) and delayed RRT initiation (n = 31; started for life-threatening indications and/or oliguria lasting more than 72 h). The primary endpoints were in-hospital mortality and renal recovery, including restoration of diuresis. Survival analysis and time to diuresis recovery were assessed using the Kaplan–Meier method and Cox regression.Results. At the time of RRT initiation, patients in the delayed group had a significantly worse metabolic profile and more severe renal impairment (higher creatinine, urea and serum potassium levels, and more pronounced acidosis; all p < 0.05). Early RRT was associated with shorter mechanical ventilation duration (58 [ 39–93] vs 66 [ 31–118] h; p = 0.038) and shorter ICU stay (12 [ 9–19] vs 15 [ 10–23] days; p = 0.045). Time to diuresis recovery was significantly shorter in the early RRT group (log-rank p = 0.015), and Cox regression showed a significantly higher probability of its recovery (HR = 2.37; 95% CI 1.15–4.91; p = 0.020). No statistically significant difference in in-hospital mortality was found between groups (29.6% vs 41.9%; p = 0.353).Conclusions. Early initiation of renal replacement therapy in patients with cardiac surgery-associated acute kidney injury is associated with faster renal recovery and reduced treatment intensity, but not with a significant reduction in mortality. These findings suggest that under current conditions early RRT mainly has an organ-protective rather than a life-saving effect.
- 16 July 2026
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 4,p. 51-61
Open AccessIMPACT OF THE TIMING OF RENAL REPLACEMENT THERAPY INITIATION ON TREATMENT OUTCOMES IN PATIENTS WITH CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY: A RETROSPECTIVE STUDY
Introduction. Acute kidney injury (AKI) following cardiac surgery remains one of the leading predictors of adverse clinical outcomes. Despite modern perfusion and intensive care technologies, the optimal timing of renal replacement therapy (RRT) initiation in AKI remains controversial.Aim. To assess the impact of RRT initiation timing on in-hospital mortality and renal function recovery in patients with AKI after cardiac surgery with cardiopulmonary bypass.Materials and methods. A retrospective single-center analysis was conducted in patients who underwent cardiac surgery with cardiopulmonary bypass between 2022 and 2025. Among 5,289 operated patients, AKI according to KDIGO criteria developed in 1,358 (25.7%), and 58 (4.27%) required RRT. Depending on treatment timing, patients were divided into early RRT initiation (n = 27; immediately after stage III AKI diagnosis) and delayed RRT initiation (n = 31; started for life-threatening indications and/or oliguria lasting more than 72 h). The primary endpoints were in-hospital mortality and renal recovery, including restoration of diuresis. Survival analysis and time to diuresis recovery were assessed using the Kaplan–Meier method and Cox regression.Results. At the time of RRT initiation, patients in the delayed group had a significantly worse metabolic profile and more severe renal impairment (higher creatinine, urea and serum potassium levels, and more pronounced acidosis; all p < 0.05). Early RRT was associated with shorter mechanical ventilation duration (58 [ 39–93] vs 66 [ 31–118] h; p = 0.038) and shorter ICU stay (12 [ 9–19] vs 15 [ 10–23] days; p = 0.045). Time to diuresis recovery was significantly shorter in the early RRT group (log-rank p = 0.015), and Cox regression showed a significantly higher probability of its recovery (HR = 2.37; 95% CI 1.15–4.91; p = 0.020). No statistically significant difference in in-hospital mortality was found between groups (29.6% vs 41.9%; p = 0.353).Conclusions. Early initiation of renal replacement therapy in patients with cardiac surgery-associated acute kidney injury is associated with faster renal recovery and reduced treatment intensity, but not with a significant reduction in mortality. These findings suggest that under current conditions early RRT mainly has an organ-protective rather than a life-saving effect.
- Open Access
- 29 June 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 34 (2)
One-Year Outcomes of Prophylactic Veno-Arterial Extracorporeal Membrane Oxygenation in High-Risk Percutaneous Coronary Intervention: A Single-Center Cohort Study
Background. High-risk percutaneous coronary intervention (HR-PCI) is increasingly performed in patients with complex coronary anatomy and severe left ventricular (LV) dysfunction. Mechanical circulatory support (MCS), including veno-arterial extracorporeal membrane oxygenation (V-A ECMO), is used to enhance procedural safety; however, its impact on long-term outcomes remains uncertain. Aim. To evaluate one-year clinical outcomes, safety, and prognostic determinants of prophylactic V-A ECMO use in patients undergoing HR-PCI. Materials and Methods. This prospective single-center observational study included 43 consecutive patients undergoing HR-PCI with planned V-A ECMO support between 2019 and 2025. The primary endpoint was all-cause mortality at 12 months. Secondary endpoints included major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of death, myocardial infarction, stroke, and repeat revascularization. Left ventricular ejection fraction (LVEF) dynamics were also assessed. Results. Procedural success was achieved in 90.7 % of patients, with successful ECMO weaning in 88.4%. Major bleeding events classified as BARC 3-5 were observed in 20.9 % of patients, while vascular complications occurred in 11.6 %. Despite favorable periprocedural outcomes, all-cause mortality at 12 months was 25.6 %, and the incidence of MACCE was 46.5 %. Nonfatal myocardial infarction and stroke occurred in 4.7 % of patients each, while repeat revascularization was performed in 11.6 % of patients. Patients with baseline LVEF <30 % had significantly higher mortality (38.9 % vs. 16.0 %; p=0.048) and a higher incidence of MACCE (61.1 % vs. 36.0 %; p=0.048). Survival analysis demonstrated significantly lower one-year survival in this group (61 % vs. 84 %; log-rank p=0.048). A modest but statistically significant improvement in LVEF was observed at 6 and 12 months. Conclusions. Prophylactic V-A ECMO in HR-PCI provides high procedural success and effective hemodynamic stabilization; however, long-term outcomes remain primarily determined by baseline myocardial function. Severe left ventricular systolic dysfunction was a key predictor of adverse one-year outcomes, suggesting that V-A ECMO may improve procedural safety but does not necessarily translate into a significant long-term prognostic benefit.
- 29 June 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 34 (2)
Open AccessOne-Year Outcomes of Prophylactic Veno-Arterial Extracorporeal Membrane Oxygenation in High-Risk Percutaneous Coronary Intervention: A Single-Center Cohort Study
Background. High-risk percutaneous coronary intervention (HR-PCI) is increasingly performed in patients with complex coronary anatomy and severe left ventricular (LV) dysfunction. Mechanical circulatory support (MCS), including veno-arterial extracorporeal membrane oxygenation (V-A ECMO), is used to enhance procedural safety; however, its impact on long-term outcomes remains uncertain. Aim. To evaluate one-year clinical outcomes, safety, and prognostic determinants of prophylactic V-A ECMO use in patients undergoing HR-PCI. Materials and Methods. This prospective single-center observational study included 43 consecutive patients undergoing HR-PCI with planned V-A ECMO support between 2019 and 2025. The primary endpoint was all-cause mortality at 12 months. Secondary endpoints included major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of death, myocardial infarction, stroke, and repeat revascularization. Left ventricular ejection fraction (LVEF) dynamics were also assessed. Results. Procedural success was achieved in 90.7 % of patients, with successful ECMO weaning in 88.4%. Major bleeding events classified as BARC 3-5 were observed in 20.9 % of patients, while vascular complications occurred in 11.6 %. Despite favorable periprocedural outcomes, all-cause mortality at 12 months was 25.6 %, and the incidence of MACCE was 46.5 %. Nonfatal myocardial infarction and stroke occurred in 4.7 % of patients each, while repeat revascularization was performed in 11.6 % of patients. Patients with baseline LVEF <30 % had significantly higher mortality (38.9 % vs. 16.0 %; p=0.048) and a higher incidence of MACCE (61.1 % vs. 36.0 %; p=0.048). Survival analysis demonstrated significantly lower one-year survival in this group (61 % vs. 84 %; log-rank p=0.048). A modest but statistically significant improvement in LVEF was observed at 6 and 12 months. Conclusions. Prophylactic V-A ECMO in HR-PCI provides high procedural success and effective hemodynamic stabilization; however, long-term outcomes remain primarily determined by baseline myocardial function. Severe left ventricular systolic dysfunction was a key predictor of adverse one-year outcomes, suggesting that V-A ECMO may improve procedural safety but does not necessarily translate into a significant long-term prognostic benefit.
- Open Access
- 12 June 2026
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 2(90),p. 72-85
Метод ниркової замісної терапії та перебіг раннього післяопераційного періоду у пацієнтів з гострим пошкодженням нирок після кардіохірургічних втручань зі штучним кровообігом
Гостре пошкодження нирок (ГПН) після кардіохірургічних втручань зі штучним кровообігом асоціюється з підвищеною летальністю та тривалішим лікуванням у відділенні інтенсивної терапії (ВІТ). Оптимальний вибір модальності та режиму ниркової замісної терапії (НЗТ) залишається дискутабельним. Метою дослідження було оцінити частоту ГПН у пацієнтів після кардіохірургічних втручань зі штучним кровообігом та вплив різних методів та режимів НЗТ на перебіг раннього післяопераційного періоду у цієї категорії пацієнтів. Методи. До ретроспективного дослідження було включено 5289 пацієнтів, які перенесли кардіохірургічні втручання із застосуванням штучного кровообігу протягом 2022–2025 роках. ГПН визначали за критеріями KDIGO. Усі дорослі пацієнти, які потребували лікування діалізними методами, були розподілені на групи залежно від модальності та режиму НЗТ: інтермітуючий гемодіаліз (IHD, n=20), повільний низькоефективний діаліз (SLED, n=21) та безперервна ниркова замісна терапія (CRRT, n=17). Первинною кінцевою точкою дослідження була госпітальна летальність. Результати. Із загальної кількості пацієнтів, які перенесли кардіохірургічні втручання, ГПН розвинулося у 1358 випадках (25,7%), в тому числі, у 58 (4,27%) - потребувало лікування методами НЗТ. Групи пацієнтів були репрезентативні за демографічними, лабораторними та інтраопераційними характеристиками. У групі CRRT, порівняно з IHD та SLED, констатовано достовірно швидша нормалізація креатиніну та лактату (p<0,05 на 1–14-ту добу), стабільніший середній артеріальний тиск (p=0,032 – 0,041), нижча потреба у VIS (12,9±5,8 vs 21,3±7,5 у IHD та 18,1±6,8 у SLED; p=0,013) та тривалість ШВЛ (CRRT - 34 [24–60] год vs 68 [42–110] у IHD і 52 [36–88] у SLED; p=0,018). Окрім того пацієнти групи CRRT мали більш короткі терміни перебування у ВІТ (10 [4–15] доби; p=0,048) та загальної госпіталізації (19 [11–29] діб; p=0,028). У групі CRRT госпітальна летальність становила 23,5% проти 45,0% у групі IHD та 38,1% - у SLED (p=0,372), однак у багатофакторному аналізі лікування CRRT достовірно асоціювалося зі зниженням ризику смерті (OR 0,50; 95% ДІ 0,23–0,99; p=0,048). Незалежними предикторами летальності були лактат, MODS, тривалість ШВЛ, сепсис і максимальний VIS. Висновки. Частота ГПН у хворих після кардіохірургічних втручань зі штучним кровообігом склала 25,7%, в коженого четвертого - п'ятого (4,27%) пацієнта з ГПН виникла необхідність проведення НЗТ. Лікування CRRT, порівняно з іншими методами, асоціювалося як і з кращими результатами щодо перебігу раннього післяопераційного періоду, так і щодо зниження ризику летальності після корекції на тяжкість стану, особливо у гемодинамічно нестабільних пацієнтів.
- 12 June 2026
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 2(90),p. 72-85
Open AccessМетод ниркової замісної терапії та перебіг раннього післяопераційного періоду у пацієнтів з гострим пошкодженням нирок після кардіохірургічних втручань зі штучним кровообігом
Гостре пошкодження нирок (ГПН) після кардіохірургічних втручань зі штучним кровообігом асоціюється з підвищеною летальністю та тривалішим лікуванням у відділенні інтенсивної терапії (ВІТ). Оптимальний вибір модальності та режиму ниркової замісної терапії (НЗТ) залишається дискутабельним. Метою дослідження було оцінити частоту ГПН у пацієнтів після кардіохірургічних втручань зі штучним кровообігом та вплив різних методів та режимів НЗТ на перебіг раннього післяопераційного періоду у цієї категорії пацієнтів. Методи. До ретроспективного дослідження було включено 5289 пацієнтів, які перенесли кардіохірургічні втручання із застосуванням штучного кровообігу протягом 2022–2025 роках. ГПН визначали за критеріями KDIGO. Усі дорослі пацієнти, які потребували лікування діалізними методами, були розподілені на групи залежно від модальності та режиму НЗТ: інтермітуючий гемодіаліз (IHD, n=20), повільний низькоефективний діаліз (SLED, n=21) та безперервна ниркова замісна терапія (CRRT, n=17). Первинною кінцевою точкою дослідження була госпітальна летальність. Результати. Із загальної кількості пацієнтів, які перенесли кардіохірургічні втручання, ГПН розвинулося у 1358 випадках (25,7%), в тому числі, у 58 (4,27%) - потребувало лікування методами НЗТ. Групи пацієнтів були репрезентативні за демографічними, лабораторними та інтраопераційними характеристиками. У групі CRRT, порівняно з IHD та SLED, констатовано достовірно швидша нормалізація креатиніну та лактату (p<0,05 на 1–14-ту добу), стабільніший середній артеріальний тиск (p=0,032 – 0,041), нижча потреба у VIS (12,9±5,8 vs 21,3±7,5 у IHD та 18,1±6,8 у SLED; p=0,013) та тривалість ШВЛ (CRRT - 34 [24–60] год vs 68 [42–110] у IHD і 52 [36–88] у SLED; p=0,018). Окрім того пацієнти групи CRRT мали більш короткі терміни перебування у ВІТ (10 [4–15] доби; p=0,048) та загальної госпіталізації (19 [11–29] діб; p=0,028). У групі CRRT госпітальна летальність становила 23,5% проти 45,0% у групі IHD та 38,1% - у SLED (p=0,372), однак у багатофакторному аналізі лікування CRRT достовірно асоціювалося зі зниженням ризику смерті (OR 0,50; 95% ДІ 0,23–0,99; p=0,048). Незалежними предикторами летальності були лактат, MODS, тривалість ШВЛ, сепсис і максимальний VIS. Висновки. Частота ГПН у хворих після кардіохірургічних втручань зі штучним кровообігом склала 25,7%, в коженого четвертого - п'ятого (4,27%) пацієнта з ГПН виникла необхідність проведення НЗТ. Лікування CRRT, порівняно з іншими методами, асоціювалося як і з кращими результатами щодо перебігу раннього післяопераційного періоду, так і щодо зниження ризику летальності після корекції на тяжкість стану, особливо у гемодинамічно нестабільних пацієнтів.
- Open Access
- 13 April 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Transplantation and artificial organs
- Vol. 4 (1-2)
The Use of Marginal Donor Hearts as an Effective Way to Expand the Donor Pool in Heart Transplantation
Introduction. The critical shortage of donor organs is the main problem in the world to provide for a need treatment of patients with terminal heart disease. One of the ways to expand the donor pool may be to expand the criteria for selecting donor hearts using the so-called "marginal donors". The aim of our study was to analyze the early and long-term results of using hearts from marginal donors in orthotopic heart transplantation in patients with terminal stage chronic heart failure. Materials and methods. From December 2019 to October 2024, the heart transplantation team of the State Institution "Heart Institute of the Ministry of Health of Ukraine" performed 106 heart transplantations. In 39 (36.7%) cases, we used hearts from "marginal" donors for orthotopic heart transplantation, in 67 cases, orthotopic heart transplantation from classical donors was performed. Results. The criteria for donor marginality were the need for regional normothermic perfusion, the ratio between the mass of the donor and the recipient <0.8, the presence of concomitant cardiosurgical pathology of the donor organ (the need for revascularization, correction of valvular defect), prolonged ischemia time of the donor organ more than 240 min., ABO incompatibility, the presence of congenital heart disease. Orthotopic heart transplantation from marginal donors provided results comparable in both the early and long-term to those of standard donor hearts. Conclusions. The use of marginal donor hearts does not significantly affect the long-term outcomes of heart transplantation, which allows for a significant expansion of the donor pool, especially for patients with high status on the waiting list.
- 13 April 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Transplantation and artificial organs
- Vol. 4 (1-2)
Open AccessThe Use of Marginal Donor Hearts as an Effective Way to Expand the Donor Pool in Heart Transplantation
Introduction. The critical shortage of donor organs is the main problem in the world to provide for a need treatment of patients with terminal heart disease. One of the ways to expand the donor pool may be to expand the criteria for selecting donor hearts using the so-called "marginal donors". The aim of our study was to analyze the early and long-term results of using hearts from marginal donors in orthotopic heart transplantation in patients with terminal stage chronic heart failure. Materials and methods. From December 2019 to October 2024, the heart transplantation team of the State Institution "Heart Institute of the Ministry of Health of Ukraine" performed 106 heart transplantations. In 39 (36.7%) cases, we used hearts from "marginal" donors for orthotopic heart transplantation, in 67 cases, orthotopic heart transplantation from classical donors was performed. Results. The criteria for donor marginality were the need for regional normothermic perfusion, the ratio between the mass of the donor and the recipient <0.8, the presence of concomitant cardiosurgical pathology of the donor organ (the need for revascularization, correction of valvular defect), prolonged ischemia time of the donor organ more than 240 min., ABO incompatibility, the presence of congenital heart disease. Orthotopic heart transplantation from marginal donors provided results comparable in both the early and long-term to those of standard donor hearts. Conclusions. The use of marginal donor hearts does not significantly affect the long-term outcomes of heart transplantation, which allows for a significant expansion of the donor pool, especially for patients with high status on the waiting list.
- Open Access
- 31 March 2026
- Published by Chetverta Khvylia in Cardiac Surgery and Interventional Cardiology
- Vol. 15 (1) , 6-13
Оцінка якості життя пацієнтів після поєднаного протезування мітрального та аортального клапанів серця залежно від наявності коронарної патології
The aim – to assess and compare quality of life (QoL) 12 months after combined mitral and aortic valve replacement according to the presence of coronary artery disease (CAD) and the extent of surgical intervention.Materials and methods. A single-center combined prospective and retrospective study (2019–2023) included 157 adult patients who underwent mitral and aortic valve replacement. Patients were allocated to three groups: Group 1 (n = 57) – double-valve replacement + concomitant coronary artery bypass grafting (CABG); Group 2 (n = 50) – double-valve replacement with angiographically confirmed CAD but without concomitant CABG; Group 3 (n = 50) – double-valve replacement without CAD. QoL was assessed at 12 months using the SF-36 questionnaire. Multivariable linear regression was performed to identify independent predictors of reduced physical functioning (PF) and mental health (MH).Results. In-hospital mortality was the highest in the concomitant CABG group (10.5 %) compared with Group 2 (2.0 %) and Group 3 (0 %) (p < 0.05). At 12 months, SF-36 scores demonstrated a graded relationship with surgical extent: the lowest QoL values were observed in Group 1, intermediate in Group 2, and the highest in Group 3 (p < 0.01–0.001). Physical functioning was 42.5 ± 6.4 in Group 1 versus 58.2 ± 5.8 in Group 2 and 64.5 ± 5.2 in Group 3 (p < 0.001). In multivariable analysis, CABG (β = –0.39; p = 0.002), age (β = –0.28; p = 0.010), and NYHA class III–IV (β = –0.33; p = 0.004) were independent predictors of reduced PF, whereas CAD without CABG was not independently associated with PF impairment (p = 0.11). For MH, CABG (β = –0.36; p = 0.004) and NYHA class III–IV (β = –0.29; p = 0.012) were independent predictors.Conclusions. QoL at 12 months after combined mitral and aortic valve replacement is strongly dependent on the extent of surgery. The poorest QoL profile is associated with concomitant CABG, while CAD per se (without CABG) is not an independent determinant of reduced QoL. These findings support tailored postoperative rehabilitation and psychological support for patients undergoing double-valve replacement with CABG.
- 31 March 2026
- Published by Chetverta Khvylia in Cardiac Surgery and Interventional Cardiology
- Vol. 15 (1) , 6-13
Open AccessОцінка якості життя пацієнтів після поєднаного протезування мітрального та аортального клапанів серця залежно від наявності коронарної патології
The aim – to assess and compare quality of life (QoL) 12 months after combined mitral and aortic valve replacement according to the presence of coronary artery disease (CAD) and the extent of surgical intervention.Materials and methods. A single-center combined prospective and retrospective study (2019–2023) included 157 adult patients who underwent mitral and aortic valve replacement. Patients were allocated to three groups: Group 1 (n = 57) – double-valve replacement + concomitant coronary artery bypass grafting (CABG); Group 2 (n = 50) – double-valve replacement with angiographically confirmed CAD but without concomitant CABG; Group 3 (n = 50) – double-valve replacement without CAD. QoL was assessed at 12 months using the SF-36 questionnaire. Multivariable linear regression was performed to identify independent predictors of reduced physical functioning (PF) and mental health (MH).Results. In-hospital mortality was the highest in the concomitant CABG group (10.5 %) compared with Group 2 (2.0 %) and Group 3 (0 %) (p < 0.05). At 12 months, SF-36 scores demonstrated a graded relationship with surgical extent: the lowest QoL values were observed in Group 1, intermediate in Group 2, and the highest in Group 3 (p < 0.01–0.001). Physical functioning was 42.5 ± 6.4 in Group 1 versus 58.2 ± 5.8 in Group 2 and 64.5 ± 5.2 in Group 3 (p < 0.001). In multivariable analysis, CABG (β = –0.39; p = 0.002), age (β = –0.28; p = 0.010), and NYHA class III–IV (β = –0.33; p = 0.004) were independent predictors of reduced PF, whereas CAD without CABG was not independently associated with PF impairment (p = 0.11). For MH, CABG (β = –0.36; p = 0.004) and NYHA class III–IV (β = –0.29; p = 0.012) were independent predictors.Conclusions. QoL at 12 months after combined mitral and aortic valve replacement is strongly dependent on the extent of surgery. The poorest QoL profile is associated with concomitant CABG, while CAD per se (without CABG) is not an independent determinant of reduced QoL. These findings support tailored postoperative rehabilitation and psychological support for patients undergoing double-valve replacement with CABG.
- Open Access
- 28 March 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 34 (1)
Retrospective Analysis of Procedural Sedation During Extracorporeal Membrane Oxygenation–Supported High-Risk Percutaneous Coronary Intervention
Introduction. High-risk percutaneous coronary intervention (HR-PCI) increasingly requires mechanical circulatory support to maintain hemodynamic stability in patients with advanced coronary artery disease and severe ventricular dysfunction. Evidence from transcatheter aortic valve implantation and emerging reports of ECMO-assisted PCI suggest that conscious sedation may reduce respiratory complications and resource utilization compared with general anesthesia; however, data specific to ECMO-supported HR-PCI are scarce. Materials and Methods. We conducted a single-center retrospective observational study including consecutive adult patients undergoing scheduled ECMO-supported HR-PCI under a procedural (conscious) sedation strategy between January 2019 and January 2026. Procedural sedation aimed to preserve spontaneous breathing (target Richmond Agitation–Sedation Scale 0 to -2). The primary endpoint was procedural success without major respiratory complications. Results. A total of 27 patients underwent scheduled ECMO-supported high-risk PCI under procedural (conscious) sedation. The primary endpoint was achieved in 23 patients (85.2 %). No cases of intraprocedural airway compromise or unplanned conversion to general anesthesia were observed. Post-procedural endotracheal intubation occurred in three patients (11.1 %) and was required only after completion of PCI. In-hospital mortality was 11.1 %, and successful weaning from ECMO at the end of the procedure was achieved in 74.1 % of cases. Respiratory complications were infrequent, and intensive care unit utilization was limited. Conclusions. In this single-center experience, procedural (conscious) sedation during scheduled ECMO-supported HR-PCI was feasible and associated with acceptable clinical outcomes, low rates of respiratory complications, and limited resource utilization. These findings extend prior evidence from structural heart interventions and recent ECMO-assisted PCI reports, supporting conscious sedation as a viable alternative to routine general anesthesia in carefully selected patients undergoing elective ECMO-supported HR-PCI at experienced centers.
- 28 March 2026
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 34 (1)
Open AccessRetrospective Analysis of Procedural Sedation During Extracorporeal Membrane Oxygenation–Supported High-Risk Percutaneous Coronary Intervention
Introduction. High-risk percutaneous coronary intervention (HR-PCI) increasingly requires mechanical circulatory support to maintain hemodynamic stability in patients with advanced coronary artery disease and severe ventricular dysfunction. Evidence from transcatheter aortic valve implantation and emerging reports of ECMO-assisted PCI suggest that conscious sedation may reduce respiratory complications and resource utilization compared with general anesthesia; however, data specific to ECMO-supported HR-PCI are scarce. Materials and Methods. We conducted a single-center retrospective observational study including consecutive adult patients undergoing scheduled ECMO-supported HR-PCI under a procedural (conscious) sedation strategy between January 2019 and January 2026. Procedural sedation aimed to preserve spontaneous breathing (target Richmond Agitation–Sedation Scale 0 to -2). The primary endpoint was procedural success without major respiratory complications. Results. A total of 27 patients underwent scheduled ECMO-supported high-risk PCI under procedural (conscious) sedation. The primary endpoint was achieved in 23 patients (85.2 %). No cases of intraprocedural airway compromise or unplanned conversion to general anesthesia were observed. Post-procedural endotracheal intubation occurred in three patients (11.1 %) and was required only after completion of PCI. In-hospital mortality was 11.1 %, and successful weaning from ECMO at the end of the procedure was achieved in 74.1 % of cases. Respiratory complications were infrequent, and intensive care unit utilization was limited. Conclusions. In this single-center experience, procedural (conscious) sedation during scheduled ECMO-supported HR-PCI was feasible and associated with acceptable clinical outcomes, low rates of respiratory complications, and limited resource utilization. These findings extend prior evidence from structural heart interventions and recent ECMO-assisted PCI reports, supporting conscious sedation as a viable alternative to routine general anesthesia in carefully selected patients undergoing elective ECMO-supported HR-PCI at experienced centers.
- Open Access
- 30 December 2025
- Published by Dnipro State Medical University
- Vol. 30 (4) , 93-97
High-risk thrombosis of a mechanical aortic valve: successful thrombolysis as a bridge or an alternative to surgery
Thrombosis of a mechanical aortic valve prosthesis is a rare, yet potentially life-threatening complication that demands urgent recognition, rapid diagnostic evaluation, and immediate therapeutic intervention. We describe a detailed clinical case of a 52-year-old male patient who developed critical thrombosis of a mechanical aortic valve prosthesis despite maintaining an adequate and well-controlled anticoagulant regimen. The patient presented with profound hemodynamic instability, markedly reduced ejection fraction, and clinical manifestations consistent with acute decompensated heart failure. On physical and instrumental examination, his condition corresponded to ASA class IV, with a calculated surgical risk of EuroSCORE II=17.28%, indicating an extremely high perioperative mortality risk. Considering both the elevated risk of surgical re-intervention and the rapidly worsening heart failure, the multidisciplinary team decided to initiate systemic thrombolytic therapy as a life-saving alternative. Thrombolysis was performed according to an accelerated protocol using intravenous alteplase at a total dose of 100 mg. Within the first hour of infusion, echocardiography revealed a clear positive trend – restoration of leaflet mobility, a notable reduction in the transprosthetic gradient, and significant improvement in myocardial contractility. Subsequent management continued in the intensive care unit with careful hemodynamic and laboratory monitoring. The patient was discharged on the eighth day in a stable condition, free of complications. Follow-up echocardiography two months later confirmed normal and sustained function of the mechanical prosthesis. This case illustrates the high efficacy of systemic thrombolysis as a viable and guideline-supported (ESC/EACTS 2021, Class I, Level B) therapeutic option when surgical treatment is contraindicated or technically impossible.
- 30 December 2025
- Published by Dnipro State Medical University
- Vol. 30 (4) , 93-97
Open AccessHigh-risk thrombosis of a mechanical aortic valve: successful thrombolysis as a bridge or an alternative to surgery
Thrombosis of a mechanical aortic valve prosthesis is a rare, yet potentially life-threatening complication that demands urgent recognition, rapid diagnostic evaluation, and immediate therapeutic intervention. We describe a detailed clinical case of a 52-year-old male patient who developed critical thrombosis of a mechanical aortic valve prosthesis despite maintaining an adequate and well-controlled anticoagulant regimen. The patient presented with profound hemodynamic instability, markedly reduced ejection fraction, and clinical manifestations consistent with acute decompensated heart failure. On physical and instrumental examination, his condition corresponded to ASA class IV, with a calculated surgical risk of EuroSCORE II=17.28%, indicating an extremely high perioperative mortality risk. Considering both the elevated risk of surgical re-intervention and the rapidly worsening heart failure, the multidisciplinary team decided to initiate systemic thrombolytic therapy as a life-saving alternative. Thrombolysis was performed according to an accelerated protocol using intravenous alteplase at a total dose of 100 mg. Within the first hour of infusion, echocardiography revealed a clear positive trend – restoration of leaflet mobility, a notable reduction in the transprosthetic gradient, and significant improvement in myocardial contractility. Subsequent management continued in the intensive care unit with careful hemodynamic and laboratory monitoring. The patient was discharged on the eighth day in a stable condition, free of complications. Follow-up echocardiography two months later confirmed normal and sustained function of the mechanical prosthesis. This case illustrates the high efficacy of systemic thrombolysis as a viable and guideline-supported (ESC/EACTS 2021, Class I, Level B) therapeutic option when surgical treatment is contraindicated or technically impossible.
- Open Access
- 25 December 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (4)
Risk Factors and Complications Structure in Patients After Surgical Treatment of Combined Aortic and Mitral Valve Disease with Concomitant Coronary Artery Disease
Introduction. Combined aortic and mitral valve lesions on the background of coronary artery disease require complex surgical correction and are associated with high perioperative risk and frequent complications. Local data on such interventions remain limited. Aim. To determine the structure of complications following combined aortic and mitral valve replacement with concomitant coronary artery bypass grafting (AVR+MVR+CABG). Materials and Methods. A retrospective single-center study included 57 patients operated in 2018-2023. Clinical, laboratory, and echocardiographic parameters were analyzed; operative risk was assessed using EuroSCORE II and STS models. Intra- and postoperative parameters were recorded; complications were classified as acute kidney injury (AKI, KDIGO), bleeding (BARC≥3), infectious, neurological, cardiac, pericarditis, rethoracotomy, and in-hospital mortality. Uni- and multivariate logistic regression was used to identify predictors of the composite endpoint (mortality / major complications) with ORs and 95 % CI (p<0.05). Results and discussion. Patients were high-risk: EuroSCORE II Me 7.0 % [4.3-10.9], STS mortality 12.2 % [8.7-17.3], STS mortality/morbidity 61.3 % [49.9-69.0]. In-hospital mortality was 10.5 % (6/57). The main causes of death were acute kidney injury progressing to multiorgan failure (n=2), acute cerebrovascular accident (n=1), pneumonia with septic shock (n=1), mediastinitis with sepsis (n=1), and acute graft thrombosis resulting in myocardial infarction (n=1). Major postoperative complications included: AKI 38.0 % (dialysis-dependent 15.8 %), infectious complications 47.4 % (mediastinitis 7.0 %), neurological disorders 43.9 % (delirium/encephalopathy), stroke 7.0 %, rethoracotomy for bleeding 12.3 %, and pericarditis 10.5 %. Typical hyperlactatemia peaked at 6 hours and normalized within 48 hours. Postoperative valve gradients remained within expected ranges; left ventricular ejection fraction at discharge was Me 50 % [41-56]. Preventive priorities include KDIGO-based AKI prevention, neuroprotection and delirium/stroke prevention strategies, strengthened infection control, blood conservation programs, and refined perioperative risk stratification. Conclusions. The combined valve–coronary cohort demonstrated high surgical risk, with elevated EuroSCORE II and STS indices and hospital mortality of 10.5 %. Functional results were satisfactory: prosthetic valve gradients remained within expected limits, and LVEF at discharge (Me 50 % [41-56]) indicated stable systolic performance. The postoperative course was dominated by an organ-dysfunction–driven complication structure, including renal complications (AKI 38.0 %, dialysis-dependent 15.8 %), infectious events (47.4 %, mediastinitis 7 %), neurological disorders (delirium/encephalopathy 43.9 %, stroke 7 %), and additional cardiac/bleeding complications (re-thoracotomy 12.3 %, pericarditis 10.5 %). The findings support the need for standardized perioperative pathways, emphasizing KDIGO-based renal protection, neuroprotection, infection control, and blood-conservation strategies, with combined EuroSCORE II+STS use for precise risk stratification.
- 25 December 2025
- Published by National Institute of Cardiovascular Surgery named after M.M. Amosov of the NAMS of Ukraine in Ukrainian journal of cardiovascular surgery
- Vol. 33 (4)
Open AccessRisk Factors and Complications Structure in Patients After Surgical Treatment of Combined Aortic and Mitral Valve Disease with Concomitant Coronary Artery Disease
Introduction. Combined aortic and mitral valve lesions on the background of coronary artery disease require complex surgical correction and are associated with high perioperative risk and frequent complications. Local data on such interventions remain limited. Aim. To determine the structure of complications following combined aortic and mitral valve replacement with concomitant coronary artery bypass grafting (AVR+MVR+CABG). Materials and Methods. A retrospective single-center study included 57 patients operated in 2018-2023. Clinical, laboratory, and echocardiographic parameters were analyzed; operative risk was assessed using EuroSCORE II and STS models. Intra- and postoperative parameters were recorded; complications were classified as acute kidney injury (AKI, KDIGO), bleeding (BARC≥3), infectious, neurological, cardiac, pericarditis, rethoracotomy, and in-hospital mortality. Uni- and multivariate logistic regression was used to identify predictors of the composite endpoint (mortality / major complications) with ORs and 95 % CI (p<0.05). Results and discussion. Patients were high-risk: EuroSCORE II Me 7.0 % [4.3-10.9], STS mortality 12.2 % [8.7-17.3], STS mortality/morbidity 61.3 % [49.9-69.0]. In-hospital mortality was 10.5 % (6/57). The main causes of death were acute kidney injury progressing to multiorgan failure (n=2), acute cerebrovascular accident (n=1), pneumonia with septic shock (n=1), mediastinitis with sepsis (n=1), and acute graft thrombosis resulting in myocardial infarction (n=1). Major postoperative complications included: AKI 38.0 % (dialysis-dependent 15.8 %), infectious complications 47.4 % (mediastinitis 7.0 %), neurological disorders 43.9 % (delirium/encephalopathy), stroke 7.0 %, rethoracotomy for bleeding 12.3 %, and pericarditis 10.5 %. Typical hyperlactatemia peaked at 6 hours and normalized within 48 hours. Postoperative valve gradients remained within expected ranges; left ventricular ejection fraction at discharge was Me 50 % [41-56]. Preventive priorities include KDIGO-based AKI prevention, neuroprotection and delirium/stroke prevention strategies, strengthened infection control, blood conservation programs, and refined perioperative risk stratification. Conclusions. The combined valve–coronary cohort demonstrated high surgical risk, with elevated EuroSCORE II and STS indices and hospital mortality of 10.5 %. Functional results were satisfactory: prosthetic valve gradients remained within expected limits, and LVEF at discharge (Me 50 % [41-56]) indicated stable systolic performance. The postoperative course was dominated by an organ-dysfunction–driven complication structure, including renal complications (AKI 38.0 %, dialysis-dependent 15.8 %), infectious events (47.4 %, mediastinitis 7 %), neurological disorders (delirium/encephalopathy 43.9 %, stroke 7 %), and additional cardiac/bleeding complications (re-thoracotomy 12.3 %, pericarditis 10.5 %). The findings support the need for standardized perioperative pathways, emphasizing KDIGO-based renal protection, neuroprotection, infection control, and blood-conservation strategies, with combined EuroSCORE II+STS use for precise risk stratification.